Allogene Therapeutics (ALLO) Earnings Date & Reports

Key Takeaways

• Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, roughly in line with Wall Street's consensus estimate of a loss of about $0.15 per share.
• Collaboration revenue was $0 for the quarter, consistent with the company's status as a clinical-stage biotechnology firm with no approved products.
• Research and development (R&D) expenses rose to $41.9 million from $31.2 million a year earlier, reflecting heavier investment across its clinical pipeline.
• Cash, cash equivalents, and investments totaled $388.9 million as of September 30, 2026, supporting a projected cash runway into 2029.
• The company reiterated full-year 2026 GAAP (Generally Accepted Accounting Principles) operating expense guidance of approximately $225 million, including roughly $35 million in non-cash stock-based compensation.
• For more detail on Allogene, readers can review Major News, Today's Price Move, Price Targets, and Forecast on dedicated analysis pages.
• Investors interested in automated trading strategies can also explore Trending AI Robots for additional market insight.

Earnings Context and Why It Matters

Allogene Therapeutics is a clinical-stage immuno-oncology company developing "off-the-shelf" allogeneic CAR T (chimeric antigen receptor T-cell) therapies for cancer and autoimmune diseases. Because it has no commercial products, quarterly earnings are less about revenue and more about cash burn, operating discipline, and clinical progress. Investors watch R&D spending and the cash balance closely, since these signal how long the company can fund its pipeline before needing additional capital. With pivotal data readouts approaching for its lead program and an expanding autoimmune initiative, this quarter offered a timely read on both financial durability and the pace of clinical execution heading into a catalyst-heavy 2027.

Reported Results

Allogene reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, versus a net loss of $41.4 million, or $0.19 per share, in the same period a year earlier. The absolute loss widened, but the per-share figure improved because the weighted-average share count rose to 346.1 million from 222.0 million. The result was essentially in line with analyst expectations of a loss of approximately $0.15 per share, and collaboration revenue was $0, matching the consensus forecast of no revenue.

On the expense side, R&D spending increased to $41.9 million from $31.2 million year over year, while general and administrative (G&A) expenses declined slightly to $12.9 million from $13.7 million. Total operating expenses were $54.8 million, up from $44.9 million. The company ended the quarter with $388.9 million in cash, cash equivalents, and investments, and it reiterated full-year 2026 GAAP operating expense guidance of approximately $225 million, including about $35 million in non-cash stock-based compensation.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for investors tracking names like Allogene Therapeutics alongside the broader biotechnology sector.

Market Reaction and Investor Sentiment

Shares of Allogene came under pressure following the announcement, declining roughly 9% in the immediate post-earnings session. The muted reaction appeared to reflect a combination of the wider absolute net loss, higher R&D spending, and investor sensitivity to cash burn and financing risk at a pre-revenue biotech. Even though the per-share result was broadly in line with consensus, the market's focus remained on milestone risk and the timeline to potential clinical catalysts rather than on the quarterly loss itself. Sentiment remains cautious, with valuation still anchored to the success of the company's pivotal-stage programs.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important variable for Allogene is not its quarterly loss but the trajectory of its clinical pipeline. The company's pivotal ALPHA3 trial, which is evaluating cema-cel in earlier-line large B-cell lymphoma (LBCL), is expected to provide a clinical update in mid-2027, with enrollment completion anticipated by year-end 2027. That readout is likely to be a defining catalyst for the stock.

A second near-term catalyst is the autoimmune program. Updated results from the ALLO-329 trial, which is studying a dual CD19/CD70 CAR T therapy across multiple autoimmune conditions, are scheduled to be presented on November 9, 2026. Investors will watch for biomarker and early clinical response data, as this program represents a potentially large market opportunity.

Finally, capital management remains a central theme. With roughly $388.9 million in cash and a runway into 2029, Allogene has meaningful financial flexibility, but rising R&D costs tied to trial expansion will need to be balanced against future financing decisions. Regulatory milestones, enrollment pacing across U.S. and international sites, and any strategic or partnership developments will all be key factors to monitor in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations